 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || LNP3794 / Boehringer Ingelheim
Trial completion, Metastases: A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov) - Mar 17, 2023
P1, N=15, Completed, Sponsor: Lupin Ltd.
Active, not recruiting --> Completed
- ||| BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Trial termination, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Feb 1, 2023
P1, N=8, Terminated, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Completed --> Terminated; Sponsor decision
- || BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Trial completion, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Dec 21, 2022
P1, N=8, Completed, Sponsor: Boehringer Ingelheim
Completed --> Terminated; Sponsor decision Terminated --> Completed
- || LNP3794 / Boehringer Ingelheim
Trial completion, Trial completion date, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Nov 14, 2022
P1, N=15, Completed, Sponsor: Boehringer Ingelheim
Terminated --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Oct 2022
- BI 894999 / Boehringer Ingelheim, BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
MEKi-based combination strategies for targeting KRAS-driven cancer (Exhibition Hall) - Sep 3, 2022 - Abstract #AACRNCIEORTC2022AACR_NCI_EORTC_289;
We also combine BI 3011441 with BI 1701963 and BI 894999 - two potent, selective, and orally bioavailable inhibitors of SOS1 and BET, respectively. In summary, we show that combining BI 3011441 with SOS1 or BET inhibitors may lead to improved responses in KRAS mutant tumors, likely by circumventing MAPK pathway-related adaptive resistance.
- || LNP3794 / Boehringer Ingelheim
Enrollment closed, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Aug 11, 2022
P1, N=15, Active, not recruiting, Sponsor: Boehringer Ingelheim
In summary, we show that combining BI 3011441 with SOS1 or BET inhibitors may lead to improved responses in KRAS mutant tumors, likely by circumventing MAPK pathway-related adaptive resistance. Recruiting --> Active, not recruiting
- BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Apr 15, 2022
P1, N=8, Terminated, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting N=124 --> 8 | Trial completion date: Jul 2024 --> Apr 2022 | Suspended --> Terminated | Trial primary completion date: Oct 2023 --> Apr 2022; Sponsor decision
- || LNP3794 / Boehringer Ingelheim
Enrollment open, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Apr 7, 2022
P1, N=12, Recruiting, Sponsor: Boehringer Ingelheim
N=124 --> 8 | Trial completion date: Jul 2024 --> Apr 2022 | Suspended --> Terminated | Trial primary completion date: Oct 2023 --> Apr 2022; Sponsor decision Active, not recruiting --> Recruiting
- |||| BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Trial suspension, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Mar 29, 2022
P1, N=124, Suspended, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Recruiting Recruiting --> Suspended
- || LNP3794 / Boehringer Ingelheim
Enrollment closed, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Mar 8, 2022
P1, N=12, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Suspended Recruiting --> Active, not recruiting
- || LNP3794 / Boehringer Ingelheim
New P1 trial, Metastases: A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov) - Jan 11, 2022
P1, N=15, Active, not recruiting, Sponsor: Lupin Ltd.
- | LNP3794 / Boehringer Ingelheim
Trial primary completion date, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Nov 18, 2021
P1, N=12, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2021 --> Mar 2022
- || BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Aug 18, 2021
P1, N=124, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Nov 2021 --> Mar 2022 Trial completion date: Sep 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Oct 2023
- ||| BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
Enrollment open, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Apr 26, 2021
P1, N=124, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Sep 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Oct 2023 Not yet recruiting --> Recruiting
- ||| BI 1701963 / Boehringer Ingelheim, LNP3794 / Boehringer Ingelheim
New P1 trial, Combination therapy, Monotherapy, Metastases: A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS]) (clinicaltrials.gov) - Apr 7, 2021
P1, N=124, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || LNP3794 / Boehringer Ingelheim
Enrollment open, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Mar 24, 2021
P1, N=12, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- BI 1701963 / Boehringer Ingelheim
[VIRTUAL] Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan. () - Mar 11, 2021 - Abstract #AACR2021AACR_3898;
Primary endpoints include dose-limiting toxicities, treatment-emergent or -related adverse events. Secondary endpoints include pharmacokinetic and pharmacodynamic properties of combination regimens and preliminary efficacy.
- || LNP3794 / Boehringer Ingelheim
New P1 trial, Metastases: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) (clinicaltrials.gov) - Feb 7, 2021
P1, N=12, Not yet recruiting, Sponsor: Boehringer Ingelheim